Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2024 Filed Feb 8, 2024 20:09 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 46 | $223.71 | $10,290.66 |
DisclosureSEC source: 0001127602-24-003945 · form4.xml · nonDerivative · entry 2 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,261.2194 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 20:09 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 134 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003945 · form4.xml · nonDerivative · entry 1 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,307.2194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:52 UTC |
Williams R SandersDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003895 · form4.xml · derivative · entry 3 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested fully on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vested fully on February 7, 2024. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:52 UTC |
Williams R SandersDirector
|
Exercise / conversionCommon Stock | 947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003895 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:51 UTC |
Wengel Kathryn EDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003893 · form4.xml · derivative · entry 3 Wengel Kathryn E · CIK 0001745955 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 944 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested fully on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vested fully on February 7, 2024. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:51 UTC |
Wengel Kathryn EDirector
|
Exercise / conversionCommon Stock | 947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003893 · form4.xml · nonDerivative · entry 1 Wengel Kathryn E · CIK 0001745955 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:50 UTC |
Parham Richelle PDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003891 · form4.xml · derivative · entry 3 Parham Richelle P · CIK 0001550078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 944 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested fully on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vested fully on February 7, 2024. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:50 UTC |
Parham Richelle PDirector
|
Exercise / conversionCommon Stock | 947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003891 · form4.xml · nonDerivative · entry 1 Parham Richelle P · CIK 0001550078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:49 UTC |
NEUPERT PETER MDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003890 · form4.xml · derivative · entry 3 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 944 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested fully on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vested fully on February 7, 2024. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:49 UTC |
NEUPERT PETER MDirector
|
Exercise / conversionCommon Stock | 947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003890 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:47 UTC |
Kong GarhengDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003889 · form4.xml · derivative · entry 3 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 944 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested fully on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vested fully on February 7, 2024. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:47 UTC |
Kong GarhengDirector
|
Exercise / conversionCommon Stock | 947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003889 · form4.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:46 UTC |
Kliphouse Kirsten MarieDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003888 · form4.xml · derivative · entry 3 Kliphouse Kirsten Marie · CIK 0001948684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 944 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested fully on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vested fully on February 7, 2024. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:46 UTC |
Kliphouse Kirsten MarieDirector
|
Exercise / conversionCommon Stock | 947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003888 · form4.xml · nonDerivative · entry 1 Kliphouse Kirsten Marie · CIK 0001948684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:45 UTC |
Gilliland Dwight GaryDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003887 · form4.xml · derivative · entry 3 Gilliland Dwight Gary · CIK 0001603769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 944 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested fully on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vested fully on February 7, 2024. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:45 UTC |
Gilliland Dwight GaryDirector
|
Exercise / conversionCommon Stock | 947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003887 · form4.xml · nonDerivative · entry 1 Gilliland Dwight Gary · CIK 0001603769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:44 UTC |
Davis Jeffrey A.Director
|
Exercise / conversionRestricted Stock Unit · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003886 · form4.xml · derivative · entry 3 Davis Jeffrey A. · CIK 0001648477 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 944 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested fully on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vested fully on February 7, 2024. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:44 UTC |
Davis Jeffrey A.Director
|
Exercise / conversionCommon Stock | 947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003886 · form4.xml · nonDerivative · entry 1 Davis Jeffrey A. · CIK 0001648477 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:43 UTC |
BELINGARD JEAN-LUCDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003885 · form4.xml · derivative · entry 4 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested fully on February 7, 2024. F5 · derivative.expiration_date: The Restricted Stock Units vested fully on February 7, 2024. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:43 UTC |
BELINGARD JEAN-LUCDirector
|
Tax withholdingCommon Stock | 95 | $223.71 | $21,252.45 |
DisclosureSEC source: 0001127602-24-003885 · form4.xml · nonDerivative · entry 2 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,781 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:43 UTC |
BELINGARD JEAN-LUCDirector
|
Exercise / conversionCommon Stock | 947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003885 · form4.xml · nonDerivative · entry 1 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:42 UTC |
ANDERSON KERRII BDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003884 · form4.xml · derivative · entry 5 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 944 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested fully on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vested fully on February 7, 2024. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:42 UTC |
ANDERSON KERRII BDirector
|
Exercise / conversionCommon Stock | 947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003884 · form4.xml · nonDerivative · entry 1 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:27 UTC |
Schechter Adam HDirector · President & CEO
|
GrantNon-qualified Stock Options · Derivative | 41,400 | $0.00 Strike: $222.28 | $0.00 |
DisclosureSEC source: 0001127602-24-003961 · form4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,400 Underlying: Common Stock · 41,400 shares Expires 2034-02-05 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:27 UTC |
Schechter Adam HDirector · President & CEO
|
GrantRestricted Stock Unit · Derivative | 13,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003961 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,491 Underlying: Common Stock · 13,380 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:26 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
GrantNon-qualified Stock Options · Derivative | 9,000 | $0.00 Strike: $222.28 | $0.00 |
DisclosureSEC source: 0001127602-24-003960 · form4.xml · derivative · entry 4 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2034-02-05 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:26 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
GrantRestricted Stock Unit · Derivative | 2,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003960 · form4.xml · derivative · entry 3 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,431 Underlying: Common Stock · 2,900 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:25 UTC |
DiVincenzo Jonathan P.EVP, Pres, Central Labs & Intl
|
GrantNon-qualified Stock Options · Derivative | 3,000 | $0.00 Strike: $222.28 | $0.00 |
DisclosureSEC source: 0001127602-24-003959 · form4.xml · derivative · entry 6 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2034-02-05 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:25 UTC |
DiVincenzo Jonathan P.EVP, Pres, Central Labs & Intl
|
GrantRestricted Stock Unit · Derivative | 980 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003959 · form4.xml · derivative · entry 5 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,540 Underlying: Common Stock · 980 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:22 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
GrantNon-qualified Stock Options · Derivative | 6,200 | $0.00 Strike: $222.28 | $0.00 |
DisclosureSEC source: 0001127602-24-003958 · form4.xml · derivative · entry 6 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,200 Underlying: Common Stock · 6,200 shares Expires 2034-02-05 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:22 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
GrantRestricted Stock Unit · Derivative | 2,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003958 · form4.xml · derivative · entry 5 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,397 Underlying: Common Stock · 2,010 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:21 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
GrantNon-qualified Stock Options · Derivative | 3,300 | $0.00 Strike: $222.28 | $0.00 |
DisclosureSEC source: 0001127602-24-003957 · form4.xml · derivative · entry 4 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,300 Underlying: Common Stock · 3,300 shares Expires 2034-02-05 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:21 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
GrantRestricted Stock Unit · Derivative | 1,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003957 · form4.xml · derivative · entry 3 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,474 Underlying: Common Stock · 1,070 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:20 UTC |
Bailey Megan D.EVP, Chief Strategy Officer
|
GrantNon-qualified Stock Options · Derivative | 1,700 | $0.00 Strike: $222.28 | $0.00 |
DisclosureSEC source: 0001127602-24-003956 · form4.xml · derivative · entry 6 Bailey Megan D. · CIK 0001975682 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,700 Underlying: Common Stock · 1,700 shares Expires 2034-02-05 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:20 UTC |
Bailey Megan D.EVP, Chief Strategy Officer
|
GrantRestricted Stock Unit · Derivative | 540 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003956 · form4.xml · derivative · entry 5 Bailey Megan D. · CIK 0001975682 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,903 Underlying: Common Stock · 540 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 556 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:19 UTC |
GRAHAM ANITA ZEVP, CHRO
|
GrantNon-qualified Stock Options · Derivative | 3,000 | $0.00 Strike: $222.28 | $0.00 |
DisclosureSEC source: 0001127602-24-003955 · form4.xml · derivative · entry 4 GRAHAM ANITA Z · CIK 0001206814 · EVP, CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2034-02-05 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:19 UTC |
GRAHAM ANITA ZEVP, CHRO
|
GrantRestricted Stock Unit · Derivative | 980 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003955 · form4.xml · derivative · entry 3 GRAHAM ANITA Z · CIK 0001206814 · EVP, CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,085 Underlying: Common Stock · 980 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 115 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:18 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
GrantNon-qualified Stock Options · Derivative | 6,900 | $0.00 Strike: $222.28 | $0.00 |
DisclosureSEC source: 0001127602-24-003954 · form4.xml · derivative · entry 6 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,900 Underlying: Common Stock · 6,900 shares Expires 2034-02-05 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:18 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
GrantRestricted Stock Unit · Derivative | 2,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003954 · form4.xml · derivative · entry 5 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,773 Underlying: Common Stock · 2,230 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:17 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
GrantNon-qualified Stock Options · Derivative | 2,100 | $0.00 Strike: $222.28 | $0.00 |
DisclosureSEC source: 0001127602-24-003953 · form4.xml · derivative · entry 4 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 2,100 shares Expires 2034-02-05 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:17 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
GrantRestricted Stock Unit · Derivative | 670 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003953 · form4.xml · derivative · entry 3 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,520 Underlying: Common Stock · 670 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:10 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
GrantNon-qualified Stock Options · Derivative | 3,600 | $0.00 Strike: $222.28 | $0.00 |
DisclosureSEC source: 0001127602-24-003948 · form4.xml · derivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires 2034-02-05 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2012 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:10 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
GrantRestricted Stock Unit · Derivative | 1,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003948 · form4.xml · derivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,025 Underlying: Common Stock · 1,160 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:09 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
GrantNon-qualified Stock Options · Derivative | 1,200 | $0.00 Strike: $222.28 | $0.00 |
DisclosureSEC source: 0001127602-24-003945 · form4.xml · derivative · entry 4 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,200 Underlying: Common Stock · 1,200 shares Expires 2034-02-05 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:09 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
GrantRestricted Stock Unit · Derivative | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003945 · form4.xml · derivative · entry 3 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,127 Underlying: Common Stock · 400 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 17:53 UTC |
Rothman PaulDirector
|
GrantRestricted Stock Unit · Derivative | 944 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003898 · form4.xml · derivative · entry 1 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,661 Underlying: Common Stock · 944 shares Expires not disclosed F1 · derivative.exercise_price: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 6, 2025. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 6, 2025. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 75 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 17:52 UTC |
Williams R SandersDirector
|
GrantRestricted Stock Unit · Derivative | 236 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003895 · form4.xml · derivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,183 Underlying: Common Stock · 236 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 6, 2025. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 6, 2025. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 98 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 17:51 UTC |
Wengel Kathryn EDirector
|
GrantRestricted Stock Unit · Derivative | 944 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003893 · form4.xml · derivative · entry 2 Wengel Kathryn E · CIK 0001745955 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,891 Underlying: Common Stock · 944 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 6, 2025. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 6, 2025. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 98 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 17:50 UTC |
Parham Richelle PDirector
|
GrantRestricted Stock Unit · Derivative | 944 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003891 · form4.xml · derivative · entry 2 Parham Richelle P · CIK 0001550078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,891 Underlying: Common Stock · 944 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 6, 2025. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 6, 2025. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 98 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 17:49 UTC |
NEUPERT PETER MDirector
|
GrantRestricted Stock Unit · Derivative | 944 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003890 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,891 Underlying: Common Stock · 944 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 6, 2025. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 6, 2025. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 98 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.